{
    "Question": "Should patients with RA initiating MTX receive oral MTX or subcutaneous (SC) MTX?",
    "Comparison": {
        "SC MTX versus Oral MTX. Data based on direct RCT evidence.": {
            "filename": "PICO 9_Comparison 1.json",
            "Explanations": {
                "a": "The study did not report on whether allocation was concealed.",
                "b": "Downgraded by one level due to serious imprecision. Confidence intervals includes both values suggesting no effect and values suggesting benefit."
            }
        }
    },
    "References": {
        "1": "Braun J. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis & Rheumatism. 2008;58(1):73."
    }
}